Showing results (191-200 of 693) with videos related to
Sort By:
Pageof 70
Clinical and Experimental Rheumatology|November 1, 1991
Elevated IgA anti-gliadin antibodies in juvenile chronic arthritisG Pellegrini, M S Scotta, S Soardo, et al.European Journal of Pediatrics|December 1, 1989
Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile chartsA Plebani, A G Ugazio, M A Avanzini, et al.International Archives of Allergy and Applied Immunology|January 1, 1987
Comparison of the frequency of atopic diseases in children with severe and partial IgA deficiencyA Plebani, V Monafo, A G Ugazio, et al.European Journal of Pediatrics|August 1, 1979
A rapid unfavorable outcome of Wegener's granulomatosis in early childhoodL Nespoli, M Duse, M A Vitiello, et al.Studies in Health Technology and Informatics|December 8, 1996
An ontology-based framework for guideline-driven medical practiceS Quaglini, L Dazzi, R Saracco, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1992
Remissions and relapses in idiopathic membranous nephropathyC Ponticelli, P Passerini, P Altieri, et al.Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|March 24, 2005
[Epidemiology and demography of uremia: data from the Lombardy Dialysis and Transplantation Registry (RLDT)]A Limido, F Malberti, F Conte, et al.Bone Marrow Transplantation|February 16, 1999
Current use and outcome of blood and marrow transplantation in childhood according to the Italian RegistryA Pession, F Locatelli, R Rondelli, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 1, 1997
Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluationF Fabrizi, S Andrulli, G Bacchini, et al.Journal of Experimental & Clinical Cancer Research : CR|February 29, 2024
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapyM Caforio, S Iacovelli, C Quintarelli, et al.Pageof 70